Search Within

Chaitanya Divgi

  1. "American Society of Hematology"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. Hematologic Malignancies, Division of (7)
  4. Molecular Imaging and Therapy Service (7)
  5. Radiology, Department of (7)
  6. Adult Leukemia (5)

More Groups

People
  1. David Scheinberg (5)
  2. George Sgouros (5)
  3. Joseph Jurcic (5)
  4. Ronald Finn (5)
  5. Steven Larson (5)
  6. Michael Mcdevitt (4)

More People

Years
  1. 2005 (1)
  2. 2004 (1)
  3. 2003 (1)
  4. 2002 (2)
  5. 1998 (1)
  6. 1994 (1)
Publications
  1. Blood (7)
Publishers
  1. American Society of Hematology (7)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin((R))) for elderly high risk patients with untreated DLBCL
    Meeting Abstract

    Hamlin, P. A.; Moskowitz, C. H.; Wegner, B. C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Dumitrescu, O.; Palomba, M. L.; Horwitz, S. M.; O'Connor, O. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
    Meeting Abstract

    Mulford, D. A.; Pandit-Taskar, N.; McDevitt, M. R.; Finn, R. D.; Weiss, M. A.; Apostolidis, C.; Morgenstern, A.; Divgi, C. R.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with Tositumomab/Iodine I131 I-Tositumomab followed by CHOP chemotherapy results in a high complete remission rate
    Meeting Abstract

    Zelenetz, A. D.; Donnelly, G.; Halaas, J.; Sgouros, G.; Humm, J.; Popplewell, L.; Reyes, S.; Maignan, K.; Campbell, C.; Moskowitz, C. H.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Sequential cytarabine and alpha-particle immunotherapy with Bismuth-213-labeled anti-CD33 monoclonal antibody HuM195 in acute myeloid leukemia (AML)
    Meeting Abstract

    Burke, J. M.; Jurcic, J. G.; Divgi, C. R.; McDevitt, M. R.; Sgouros, G.; Finn, R. D.; Larson, S. M.; Scheinberg, D. A.
    Blood (2002)

    Fulltext@MSK | Save
  • Targeted α particle immunotherapy for myeloid leukemia
    Journal Article

    Jurcic, J. G.; Larson, S. M.; Sgouros, G.; McDevitt, M. R.; Finn, R. D.; Divgi, C. R.; Ballangrud, A. M.; Hamacher, K. A.; Ma, D.; Humm, J. L.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • Potential for myeloablation with yttrium-90-labeled HuM195 (anti-CD33): A phase I trial in advanced myeloid leukemias
    Meeting Abstract

    Jurcic, J. G.; Divgi, C. R.; McDevitt, M. R.; Ma, D.; Sgouros, G.; Finn, R. D.; Larson, S. M.; Scheinberg, D. A.
    Blood (1998)

    Fulltext@MSK | Save
  • A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
    Journal Article

    Caron, P. C.; Jurcic, J. G.; Scott, A. M.; Finn, R. D.; Divgi, C. R.; Graham, M. C.; Jureidini, I. M.; Sgouros, G.; Tyson, D.; Old, L. J.; more...
    Blood (1994)

    Fulltext@MSK | Save